If strategic outsourcing for development, regulatory, and clinical support is a core component of a company’s business plan, then Cato BioVenture’s investment model can make a positive difference in the company’s overall success.
Durham, NC (PRWEB) April 23, 2013
Experts from Cato BioVentures are attending BIO International Convention 2013 this week in Chicago, Illinois. This global event for Biotechnology brings together all industry segments from around the world, ready to meet and build strategic partnerships.
The event includes industry education, networking, BIO Business Forum partnering, and over 2,000 companies showcasing the latest technologies, products, and services in the BIO Exhibition.
Attending experts include: Daniel Pharand, C.P.A., C.A., Principal of Cato BioVentures and Chief Financial Officer of Cato Research as well as Chief Executive Officer and Chief Financial Officer of Cancer Advances; Jo Cato, Ph.D., Vice President of Cato BioVentures and Chief Operating Officer of Cato Research; and David Gee, Strategic Business Developer of Cato Research.
These experts, along with other Cato BioVentures representatives, will participate in networking and attending one-on-one partnering meetings.
To set up a meeting with Cato BioVentures or Cancer Advances, please call 919-361-2286.
For more information, you may visit: http://www.cato.com/marketing/2013/2013-BioInternational_CatoBioVentures.html
About Cato BioVentures
Cato BioVentures is the venture capital affiliate of Cato Research, a global contract research and development organization (CRO). For over 25 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital™ in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry’s research and development productivity. If strategic outsourcing for development, regulatory, and clinical support is a core component of a company’s business plan, then Cato BioVenture’s investment model can make a positive difference in the company’s overall success. For more information about Cato BioVentures, call 919-361-2286 or visit http://www.catobioventures.com.
About Cato Research
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost effectiveness. For more information about Cato Research, visit http://www.cato.com.